SF1Alternative Names: Sonoflora 1; Sonosensitizing agent - SonneMed
Latest Information Update: 15 Sep 2015
At a glance
- Originator SonneMed
- Mechanism of Action Singlet oxygen stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 15 Sep 2015 Discontinued - Phase-I/II for Breast cancer (Late-stage disease) in USA (Sublingual)
- 08 Sep 2008 Phase-I/II clinical trials in Advanced breast cancer in USA (Sublingual)